VTV THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25 USD | +1.93% |
|
0.00% | +117.39% |
| Mar. 14 | VTv Therapeutics Inc. Announces Board Changes | CI |
| Mar. 13 | VTv Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2022 | 2.02M | Sales 2023 | - | Capitalization | 23.43M |
|---|---|---|---|---|---|
| Net income 2022 | -19M | Net income 2023 | -20M | EV / Sales 2022 | 21.1 x |
| Net cash position 2022 | 11.42M | Net cash position 2023 | 8.98M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-2.59
x | P/E ratio 2023 |
-1.18
x | Employees | 16 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 41.41% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +1.93% | ||
| Current month | +6.25% | ||
| 1 month | +38.89% | ||
| 3 months | +173.37% | ||
| 6 months | +34.09% | ||
| Current year | +117.39% |
1 week
23.86
25.69
1 month
17.1330.99
Current year
7.3830.99
1 year
7.3839.60
3 years
7.38115.20
5 years
7.38190.00
10 years
7.38560.00
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Sekhri
CEO | Chief Executive Officer | 66 | 22-07-31 |
Steven Tuch
DFI | Director of Finance/CFO | 56 | 22-12-07 |
Vanessa McDade
ADM | Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Srini Akkaraju
BRD | Director/Board Member | 56 | Feb. 26 |
Paul Sekhri
CEO | Chief Executive Officer | 66 | 22-07-31 |
Richard Nelson
BRD | Director/Board Member | 54 | 20-11-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 25 | +1.93% | 11,658 |
| 24-04-12 | 24.53 | -3.48% | 4,676 |
| 24-04-11 | 25.41 | +0.43% | 2,476 |
| 24-04-10 | 25.3 | +1.20% | 3,745 |
| 24-04-09 | 25 | 0.00% | 1,472 |
Delayed Quote Nasdaq, April 15, 2024 at 04:30 pm EDT
More quotes
vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes HPP593, Nrf2/Bach1 Modulator Program, Azeliragon and HPP3033.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +117.39% | 59.67M | |
| -2.34% | 102B | |
| +2.31% | 97.22B | |
| +4.22% | 22.27B | |
| -16.72% | 20.84B | |
| -4.50% | 19.19B | |
| -41.75% | 16.76B | |
| -23.26% | 14.76B | |
| -0.02% | 13.54B | |
| +22.69% | 11.53B |
- Stock Market
- Equities
- VTVT Stock
